Edesa Biotech, Inc. (EDSA)
2.01
+0.05
(+2.55%)
USD |
NASDAQ |
Nov 18, 15:09
Edesa Biotech Enterprise Value : 16.96M for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 16.96M |
| November 16, 2026 | 16.29M |
| November 13, 2026 | 16.77M |
| November 12, 2026 | 18.12M |
| November 11, 2026 | 19.47M |
| November 10, 2026 | 17.54M |
| November 09, 2026 | 22.07M |
| November 06, 2026 | 18.69M |
| November 05, 2026 | 18.60M |
| November 04, 2026 | 18.98M |
| November 03, 2026 | 20.04M |
| November 02, 2026 | 21.58M |
| October 30, 2026 | 22.84M |
| October 29, 2026 | 24.09M |
| October 28, 2026 | 22.74M |
| October 27, 2026 | 23.42M |
| October 26, 2026 | 23.03M |
| October 23, 2026 | 24.76M |
| October 22, 2026 | 24.67M |
| October 21, 2026 | 25.53M |
| October 20, 2026 | 25.25M |
| October 19, 2026 | 24.86M |
| October 16, 2026 | 22.84M |
| October 15, 2026 | 23.80M |
| October 14, 2026 | 23.61M |
| Date | Value |
|---|---|
| October 13, 2026 | 25.49M |
| October 12, 2026 | 26.40M |
| October 09, 2026 | 31.89M |
| October 08, 2026 | 33.34M |
| October 07, 2026 | 35.60M |
| October 06, 2026 | 33.92M |
| October 05, 2026 | 35.75M |
| October 02, 2026 | 35.26M |
| October 01, 2026 | 36.71M |
| September 30, 2026 | 38.64M |
| September 29, 2026 | 32.37M |
| September 28, 2026 | 33.24M |
| September 25, 2026 | 36.71M |
| September 24, 2026 | 36.90M |
| September 23, 2026 | 36.32M |
| September 22, 2026 | 37.29M |
| September 21, 2026 | 37.67M |
| September 18, 2026 | 37.96M |
| September 17, 2026 | 37.96M |
| September 16, 2026 | 35.36M |
| September 15, 2026 | 37.77M |
| September 14, 2026 | 37.91M |
| September 11, 2026 | 38.83M |
| September 10, 2026 | 42.97M |
| September 09, 2026 | 43.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProMIS Neurosciences, Inc. | -15.32M |
| Oncolytics Biotech, Inc. | 48.55M |
| Sangamo Therapeutics, Inc. | 37.32M |
| Sarepta Therapeutics, Inc. | 1.758B |
| Anixa Biosciences, Inc. | 77.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.408M |
| Total Expenses (Quarterly) | 5.408M |
| EPS Diluted (Quarterly) | -0.6003 |
| Earnings Yield | -84.17% |
| Normalized Earnings Yield | -86.52 |